Condition
PASC Post Acute Sequelae of COVID-19
Total Trials
2
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
Treatment Research
4 treatments under study, led by A2 ¹⁸ffarag Petct 60min Dynamic Only
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Early Phase 1 (1)
Trial Status
Recruiting2
Clinical Trials (2)
Research Network
Common Treatments
- A2 ¹⁸ffarag Petct 60min Dynamic Only1
- A1 ¹⁸ffarag Petct 90min Dynamic 4h Static1
- B2 ¹⁸ffarag Petct 60min Dynamic Only1
- B1 ¹⁸ffarag Petct 90min Dynamic 4h Static1
Active Sponsors
- University of California, Davis1
- University of California, San Francisco1
- National Institute of Allergy and Infectious Diseases (NIAID)1
- National Institute of Neurological Disorders and Stroke (NINDS)1
Top Investigators
University of California, Davis
National Institute of Neurological Disorders and Stroke (NINDS)